Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NRX Pharmaceuticals ( (NRXP) ) has issued an announcement.
On September 24, 2025, NRx Pharmaceuticals announced that the FDA granted a Suitability Petition for its preservative-free ketamine product, KETAFREE™, allowing the company to re-file its Abbreviated New Drug Application. This development aligns with the administration’s goals of re-shoring drug manufacturing and removing toxic preservatives, potentially enhancing NRx’s market position in the $750 million ketamine market.
The most recent analyst rating on (NRXP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
NRX Pharmaceuticals is navigating significant financial hurdles with net losses and negative equity, typical for early-stage biotech firms. However, strategic initiatives and drug development progress provide potential upside. Technical analysis and valuation reflect speculative potential, with the stock currently exhibiting mixed technical signals. The positive outlook from the earnings call highlights strategic moves that could improve the company’s financial health if successful.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is working on products such as NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone, both of which have received special designations from regulatory bodies.
Average Trading Volume: 348,273
Technical Sentiment Signal: Buy
Current Market Cap: $71.07M
See more insights into NRXP stock on TipRanks’ Stock Analysis page.